## SEQUENCE LISTING

<110 > Glaxo Group Limited. Bonnefoy, Jean-Yves Ellis, Jonathan H

<120> Antibody.

<130> PG3433

<140>

<141>

<150> GB 9809839.5 <151> 1998-05-09

<160> 53

<170> PatentIn Ver. 2.1

<210> 1

<211> 415

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (3)..(413)

20

<400> 1

aa got tta cag tta ctc agc aca cag gac ctc acd atg gat ttt ggg Ala Leu Gln Leu Leu Ser Thr Gln Asp Leu Thr Met Asp Phe Gly 15 10 1

ctg att ttt ttt att gtt ctt tta aaa ggg gtc cag agt gaa gtg aag Leu Ile Phe Phe Ile Val Leu Leu Lys Gly Val Gln Ser Gly Val Lys

25

<222> (3)..(437)

ctt	gag	gag	tct	gga	gga	ggc	ttg	gtg	caa	cct	gga	gga	tcc	atg	aaa	143
Leu	Glu	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	Ser	Met	Lys	
			35					40					45			
ctc	tcc	tgt	gta	gcc	tct	gga	ttt	act	ttc	agt	ggc	tac	tgg	atg	tct	191
Leu	Ser	Cys	Val	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Gly	Tyr	Trp	Met	Ser	
		50					55					60				
tgg	gtc	cgc	cag	tct	cca	gag	aag	ggg	ctt	gag	tgg	gtt	gct	gaa	att	239
Trp	Val	Arg	Gln	Ser	Pro	Glu	Lys	Gly	Leu	Glu	Trp	Val	Ala	Glu	Ile	
	65					70					75					
aga	ttg	aaa	tct	gat	aat	tat	gca	aca	cat	tat	gcg	gag	tct	gtg	aaa	287
Arg	Leu	Lys	Ser	Asp	Asn	Tyr	Ala	Thr	His	Tyr	Ala	Glu	Ser	Val	Lys	
80					85					90					95	
ggg	aag	ttc	acc	atc	tca	aga	gat	gat	tcc	aaa	agt	cgt	ctc	tac	ctg	335
Gly	Lys	Phe	Thr	Ile	ser	Arg	Asp	Asp	Ser	Lys	ser	Arg	Leu	Tyr	Leu	
				100					105					110		
caa	atg	aac	agc	tta	aga	gct	gaa	gac	agt	gga	gtt	tat	tac	tgt	aca	383
Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Ser	Gly	Val	Tyr	Tyr	Cys	Thr	
			115					120					125			,
gat	ttc	ata	gac	tgg	ggc	caa	<b>g</b> gg	aca	cta	gt						415
Asp	Phe	Ile	Asp	Trp	Gly	Gln	Gly	Thr	Leu							
		130					135									
<210	)> 2															
<21	1> 43	37														
<212	2> DI	AV														
<21	3> Mi	ıs mı	ıscu.	lus												
<220	)>															
<22	1> CI	os														

									3							
<40	00> 2	2														
aa	gct	tta	cag	tta	ctc	agc	aca	cag	gac	ctc	acc	atg	agg	ttc	tct	47
	Ala	Leu	Gln	Leu	Leu	Ser	Thr	Gln	Asp	Leu	Thr	Met	Arg	Phe	Ser	
	1				5					10					15	
												-	_	• -	ggg	95
Val	Gln	Phe	e Leu	Gly	Val	Leu	Met	Phe	Trp	Ile	Ser	Gly	' Val	Ser	Gly	
				20	l				25	,				30	1	
															gga	143
Asp	Ile	· Val			Gln	Asp	Glu			Asn	Pro	Val		Ser	Gly	
			35					40					45			
	<b>.</b>				<b>.</b>											
-		_				_			-	_	_		•		aag	191
GIU	ser	50		TIE	ser	Cys	_		ser	гÃа	ser	Leu		Tyr	гàг	
		50	,				55					60				
aat	aaa		. 202	tac	++a	- aa+	taa	+++	cta		202	cca	~~~	-	t at	239
										-	_	Pro				239
	65			- 1, -	200	70		2	204	0.1	75		Gly	GIII	Der	
						, ,										
cct	cag	cto	ctq	atq	tat	ttq	atq	tcc	acc	cat	qca	tca	aaa	atc	tca	287
												Ser		_		
80					85					90					95	
gac	cgg	ttt	agt	ggc	agt	ggg	tca	ggc	aca	gat	ttc	acc	ctg	gaa	atc	335
Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Glu	Ile	
				100					105					110		
agt	aga	gtg	aag	gct	gag	gat	gtg	ggt	gtg	tat	tac	tgt	caa	caa	ctt	383
Ser	Arg	Val	Lys	Ala	Glu	Asp	Val	Gly	Val	Tyr	Tyr	Cys	Gln	Gln	Leu	

gta gag tat cca ttc acg ttc ggc tcg ggg aca aag ttg gaa ata aaa 431 Val Glu Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 130 135 140

120

115

WO 99/58679

4

```
437
cgt acg
Arg Thr
    145
<210> 3
<211> 16
<212> PRT
<213> Mus musculus
<400> 3
Arg Ser Ser Lys Ser Leu Leu Tyr Lys Asp Gly Lys Thr Tyr Leu Asn
  1
                  5
                                      10
                                                          15
<210> 4
<211> 48
<212> DNA
<213> Mus musculus
<220>
<221> CDS
<222> (1)..(48)
<400> 4
cgc tcg agt aag agt ctc ctg tat aag gat ggg aag aca tac ttg aat
Arg Ser Ser Lys Ser Leu Leu Tyr Lys Asp Gly Lys Thr Tyr Leu Asn
                                                          15
  1
                  5
                                      10
<210> 5
<211> 7
<212> PRT
<213> Mus musculus
<400> 5
Leu Met Ser Thr Arg Ala Ser
  1
                  5
```

s as a s

PCT/GB99/01434 WO 99/58679

5

מו בור בין יויה ממום מווי זה מווו מווי זו ווי יו יוויילי יוה יומי

21

27

<210> 6 <211> 21

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (1)..(21)

<400> 6

ttg atg tcc acc cgg gca tca

Leu Met Ser Thr Arg Ala Ser

5 1

<210> 7

<211> 9

<212> PRT

<213> Mus musculus

<400> 7

Gln Gln Leu Val Glu Tyr Pro Phe Thr 5

<210> 8

<211> 27

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (1)..(27)

<400> 8

caa cag ctg gta gag tat cca ttc acg Gln Gln Leu Val Glu Tyr Pro Phe Thr

1

WO 99/58679 PCT/GB99/01434

6

<210> 9

<211> 5

<212> PRT

<213> Mus musculus

<400> 9

Gly Tyr Trp Met Ser

1

5

<210> 10

<211> 15

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (1)..(15)

<400> 10

ggc tac tgg atg tcc

Gly Tyr Trp Met Ser

1

5

<210> 11

<211> 19

<212> PRT

<213> Mus musculus

<400> 11

Glu Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser

1

5

10

15

15

Val Lys Gly

There are that it if it man that me were notes now now now one in it.

57

WO 99/58679 PCT/GB99/01434

7

<210> 12

<211> 57

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (1)..(57)

<400> 12

gaa att aga ttg aaa tct gat aat tat gca aca cat tat gcg gag tct 48 Glu Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser

1 5 10 15

gtg aag ggg

Val Lys Gly

<210> 13

<400> 13

000

<210> 14

<400> 14

000

<210> 15

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
sequence

<400> 15

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly

1

.

10

Val His Ser

<210> 16

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
sequence

<400> 16

Met Ala Trp Val Trp Thr Leu Leu Phe Leu Met Ala Ala Ala Gln Ser 1 5 10 15

Ala Gln Ala

<210> 17

<211> 348

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Humanised
 anti-CD23 antibody light chain variable region

<220>

<221> CDS

<222> (1)..(348)

<400> 17

gat att gtg atg act cag tct cca ctc tcc ctg ccc gtc acc cct gga 48
Asp Il Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15

gag	ccg	gcc	tcc	atc	tcc	tgt	cgc	tcg	agt	aag	agt	ctc	ctg	tat	aag	96
Glu	Pro	Ala	Ser	Ile	Ser	Cys	Arg	Ser	Ser	Lys	Ser	Leu	Leu	Tyr	Lys	
			20					25				*	30			
gat	999	aag	aca	tac	ttg	aat	tgg	tac	ctg	cag	aag	cca	ggg	cag	tct	144
Asp	Gly	Lys	Thr	Tyr	Leu	Asn	Trp	Tyr	Leu	Gln	Lys	Pro	Gly	Gln	Ser	
		35					40					45				
cca	cag	ctc	ctg	atc	tat	ttg	atg	tcc	acc	cgg	gca	tca	ggg	gtc	cct	192
Pro		Leu	Leu	Ile	Tyr		Met	Ser	Thr	Arg		Ser	Gly	Val	Pro	
	50					55					60					
_		ttc	_		_											240
_	Arg	Phe	Ser	Gly		Gly	Ser	Gly	Thr	-	Phe	Thr	Leu	Lys		
65					70					75					80	
																200
	-	gtg														288
ser	Arg	Val	GIU		GIU	Asp	vaı	GIY		Tyr	Tyr	Cys	GIN		ren	
				85					90					95		
nt a	asa	tat	cca	ttc	aca	ttc	aac	caa	aaa	acc	aan	ata	gag	atc	222	336
	-	Tyr														333
• • •	014	-7-	100	1110	****	1 110	O.J	105	<b>4.</b>	****	טעם	•••	110	110	2,5	
cat	aco	gtg	act													348
-	-	Val	_													
		115														
<210	)> 18	3														
<211	l> 13	335														

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Humanised anti-CD23 antibody heavy chain variable region.

<220	)>															
<221	L> CI	s														
<222	2> (3	L) (	(1335	5)												
<400	> 18	3														
gag	gtg	cag	ctg	gtg	gag	tct	ggg	gga	ggc	ttg	gta	aag	ccc	ggg	<b>gg</b> g	48
Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Lys	Pro	Gly	Gly	
1				5					10					15		
tcc	ctt	aga	ctc	tcc	tgt	gca	gct	agc	gga	ttc	act	ttc	agt	ggc	tac	96
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Gly	Tyr	
			20					25					30			
tgg	atg	tcc	tgg	gtc	cgc	cag	gct	cca	ggg	aag	ggg	ctc	gag	tgg	gtt	144
Trp	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
		35					40					45				
gct	gaa	att	aga	ttg	aaa	tct	gat	aat	tat	gca	aca	cat	tat	gcg	gag	192
Ala	Glu	Ile	Arg	Leu	Lys	Ser	Asp	Asn	Tyr	Ala	Thr	His	Tyr	Ala	Glu	
	50					55					60					
tct	gtg	aag	ggg	aaa	ttc	acc	atc	tca	aga	gat	gat	tca	aaa	tct	aga	240
Ser	Val	Lys	Gly	Lys	Phe	Thr	Ile	Ser	Arg	Asp	Asp	Ser	Lys	Ser	Arg	
65					70					75					80	
-		_		-		-	_				-		_	gtg		288
Leu	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Lys		Glu	Asp	Thr	Ala	Val	Tyr	
				85					90					95		
			-			_							-	acc	-	336
Tyr	Cys	Thr		Phe	Ile	Asp	Trp	_	Gln	Gly	Thr	Leu		Thr	Val	
			100					105					110			
								4				_4 -				204
		_			_			-	-			-	-	ccc		384
ser	ser	wra	ser	Inr	ьys	GTÄ	Pro	ser	val	rne	rro	reu	wrg	Pro	ser	

tcc	aag	agc	acc	tct	ggg	ggc	aca	gcg	gcc	ctg	ggc	tgc	ctg	gtc	aag	432
Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	
	130					135					140					
gac	tac	ttc	ccc	gaa	ccg	gtg	acg	gtg	tcg	tgg	aac	tca	ggc	gcc	ctg	480
Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	
145					150					155					160	
acc	age	ggc	gtg	cac	acc	ttc	ccg	gct	gtc	cta	cag	tcc	tca	gga	ctc	528
	_										Gln					
		-		165					170					175		
tac	tee	ctc	agc	agc	ata	ata	acc	ata	ccc	tcc	agc	agc	tta	aac	acc	576
											Ser					
- , -	001	200	180	<b>D</b>				185					190			
			100					100					170			
		+	24.0	+~~	220	ata	22+	030	220	200	agc	220	200	220	ata	624
-																024
GIN	Thr	_	TIE	Cys	ASII	vai		urs	Lys	PIO	Ser	205	1111	гур	Vai	
		195					200					203				
											4					670
_	_										act					672
Asp	_	Lys	Val	Glu	Pro		ser	Cys	Asp	Lys	Thr	HIS	Thr	Cys	Pro	
	210					215					220					
_	_										tca					720
Pro	Cys	Pro	Ala	Pro	Glu	Leu	Ala	Gly	Ala	Pro	Ser	Val	Phe	Leu	Phe	
225					230					235					240	
ccc	cca	aaa	ccc	aag	gac	acc	ctc	atg	atc	tcc	cgg	acc	cct	gag	gtc	768
Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	
				245					250					255		
aca	tgc	gtg	gtg	gtg	gac	gtg	agc	cac	gaa	gac	cct	gag	gtc	aag	ttc	816
Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	
			260					265					270			

aac	<b>tg</b> g	tac	gtg	gac	ggc	gtg	gag	gtg	cat	aat	gcc	aag	aca	aag	ccg	864
Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	
		275					280					285				
cgg	gag	gag	cag	tac	aac	agc	acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	912
Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	
	290					295					300					
gtc	ctg	cac	cag	gac	tgg	ctg	aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	960
Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	
305					310					315					320	
tcc	aac	aaa	gcc	ctc	cca	gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	1008
											Thr					
		•		325					330	-				335		
aaa	aaa	cag	CCC	cga	gaa	cca	cag	ata	tac	acc	ctg	ccc	cca	tcc	caa	1056
											Leu					
	1								- 4 -						5	
			340					345					350			
			340					345					350			
gat	gag	cta		nss	aac	cad	atc		cta	acc	tac	cta		aaa	aac	1104
_	-	-	acc	_				agc			tgc		gtc			1104
_	-	Leu	acc	_			Val	agc			tgc Cys	Leu	gtc			1104
_	-	-	acc	_				agc					gtc			1104
Asp	Glu	Leu 355	acc Thr	Lys	Asn	Gln	Val 360	agc Ser	Leu	Thr	Cys	Leu 365	gtc Val	Lys	Gly	
Asp	Glu	Leu 355	acc Thr	Lys	Asn	Gln gcc	Val 360 gtg	agc Ser gag	Leu tgg	Thr gag	Cys agc	Leu 365 aat	gtc Val ggg	Lys cag	Gly	1104
Asp	Glu tat Tyr	Leu 355	acc Thr	Lys	Asn	Gln gcc Ala	Val 360 gtg	agc Ser gag	Leu tgg	Thr gag	Cys agc Ser	Leu 365 aat	gtc Val ggg	Lys cag	Gly	
Asp	Glu	Leu 355	acc Thr	Lys	Asn	Gln gcc	Val 360 gtg	agc Ser gag	Leu tgg	Thr gag	Cys agc	Leu 365 aat	gtc Val ggg	Lys cag	Gly	
Asp ttc Phe	Glu tat Tyr 370	Leu 355 ccc Pro	acc Thr agc Ser	Lys gac Asp	Asn atc Ile	Gln gcc Ala 375	Val 360 gtg Val	agc Ser gag Glu	tgg Trp	Thr gag Glu	agc ser 380	Leu 365 aat Asn	gtc Val ggg Gly	Lys cag Gln	Gly ccg Pro	1152
ttc Phe	Glu tat Tyr 370	Leu 355 ccc Pro	acc Thr agc Ser	Lys gac Asp	atc Ile	gcc Ala 375	Val 360 gtg Val	agc Ser gag Glu	tgg Trp	Thr gag Glu ctg	agc ser 380	Leu 365 aat Asn	gtc Val ggg Gly	Lys cag Gln ggc	ccg Pro	
ttc Phe	Glu tat Tyr 370	Leu 355 ccc Pro	acc Thr agc Ser	Lys gac Asp	atc Ile	gcc Ala 375	Val 360 gtg Val	agc Ser gag Glu	tgg Trp	Thr gag Glu ctg	agc ser 380	Leu 365 aat Asn	gtc Val ggg Gly	Lys cag Gln ggc	ccg Pro	1152
ttc Phe	Glu tat Tyr 370	Leu 355 ccc Pro	acc Thr agc Ser	Lys gac Asp	atc Ile	gcc Ala 375	Val 360 gtg Val	agc Ser gag Glu	tgg Trp	Thr gag Glu ctg	agc ser 380	Leu 365 aat Asn	gtc Val ggg Gly	Lys cag Gln ggc	ccg Pro	1152
ttc Phe gag	Glu tat Tyr 370	Leu 355 ccc Pro	acc Thr agc Ser	Lys gac Asp	atc Ile acc	gcc Ala 375	Val 360 gtg Val	agc Ser gag Glu	tgg Trp	Thr gag Glu ctg Leu	agc ser 380	Leu 365 aat Asn	gtc Val ggg Gly	Lys cag Gln ggc	ccg Pro tcc Ser	1152
ttc Phe gag Glu 385	Glu tat Tyr 370 aac Asn	Leu 355 ccc Pro aac Asn	acc Thr agc Ser tac	Lys gac Asp aag	atc Ile acc Thr	gcc Ala 375 acg Thr	Val 360 gtg Val cct Pro	agc Ser gag Glu ccc Pro	tgg Trp gtg Val	gag Glu ctg Leu 395	agc ser 380	Leu 365 aat Asn tcc Ser	gtc Val ggg Gly gac Asp	cag Gln ggc Gly	ccg Pro tcc Ser 400	1152
ttc Phe gag Glu 385	tat Tyr 370 aac Asn	Leu 355 ccc Pro aac Asn	acc Thr agc Ser tac Tyr	Lys gac Asp aag Lys	atc Ile acc Thr 390	gcc Ala 375 acg Thr	Val 360 gtg Val cct Pro	agc Ser gag Glu ccc Pro	tgg Trp gtg Val	gag Glu ctg Leu 395	agc ser 380 gac	Leu 365 aat Asn tcc ser	gtc Val ggg Gly gac Asp	cag Gln ggc Gly	ccg Pro tcc Ser 400	1152
ttc Phe gag Glu 385	tat Tyr 370 aac Asn	Leu 355 ccc Pro aac Asn	acc Thr agc Ser tac Tyr	Lys gac Asp aag Lys	atc Ile acc Thr 390	gcc Ala 375 acg Thr	Val 360 gtg Val cct Pro	agc Ser gag Glu ccc Pro	tgg Trp gtg Val	gag Glu ctg Leu 395	agc Ser 380 gac Asp	Leu 365 aat Asn tcc ser	gtc Val ggg Gly gac Asp	cag Gln ggc Gly	ccg Pro tcc Ser 400	1152

and put mit to the training man.

111 1 1 TE 1

ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa tga 1335 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 <210> 19 <211> 57 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 19 gatgaagett tacagttact cagcacacag gacctcacca tggattttgg gctgatt <210> 20 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 20 25 gatggactag tgtcccttgg cccca <210> 21 <211> 57 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo

4 •

<400> 21	
gatgaagett tacagttact cagcacacag gaceteacea tgaggttete tgtteag	57
<210> 22	
<211> 28	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Oligo	
<400> 22	
gatgcgtacg tytkatytcc avcttkgt	28
<210> 23	
<211> 30	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Oligo	
<400> 23	
gatcaagctt ctctacagtt actgagcaca	30
<210> 24	
<211> 63	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Oligo	
<400> 24	
aatcaagtat gtcttcccat ccttatacag gagactctta ctcgagcgac aggagatgga	60
ggc	63

<210> 25	
<211> 63	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Oligo	
<400> 25	
cgctcgagta agagtctcct gtataaggat gggaagacat acttgaattg gtacctgcag	60
aag	63
<210> 26	
<211> 36	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Oligo	
<400> 26	
tgatgcccgg gtggacatca aatagatcag gagctg	36
<210> 27	
<211> 36	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Oligo	
<400> 27	
ttgatgtcca cccgggcatc aggggtccct gacagg	36
<210> 28	
<211> 84	
<212> DNA	
<213> Artificial Sequence	

n 5 mai mi. m mi. mm mm. iim air min

<220> <223> Description of Artificial Sequence: Oligo <400> 28 agccacctga cgtttgatct ccaccttggt cccttggccg aacgtgaatg gatactctac 60 cagctgttga cagtaataaa cccc 84 <210> 29 <211> 60 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 29 acacgaaget teaceatgge ttgggtgtgg acettgetat teetgatgge ggeegeecaa 60 <210> 30 <211> 66 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 30 ctttaccaag cctcccccag actccaccag ctgcacctct gcttgggcac ttttgggcggc 60 66 cgccat <210> 31 <211> 60 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo

. . . . . .

<400> 31 ttggtaaagc ccggggggtc ccttagactc tcctgtgcag ctagcggatt cactttcagt 60 <210> 32 <211> 60 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 32 ccccttccct ggagcctggc ggacccagga catccagtag ccactgaaag tgaatccgct 60 <210> 33 <211> 60 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 33 gggaaggggc tcgagtgggt tgctgaaatt agattgaaat ctgataatta tgcaacacat 60 <210> 34 <211> 60 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo

<400> 34
atcatctctt gagatggtga atttcccctt cacagactcc gcataatgtg ttgcataatt 60

. . . . . .

ה.מו מה מוום מוום והו וו יוש" מווו יה וו יה לחוף 'יה לחוף

WO 99/58679 PCT/GB99/01434

18

<210> 35 <211> 66 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 35 atctcaagag atgattcaaa atctagactg tatctgcaaa tgaacagcct gaaaaccgag 60 gacaca 66 <210> 36 <211> 69 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 36 ggtgactagt gttccctggc cccagtctat gaaatctgta cagtaataca cggctgtgtc 60 69 ctcggtttt <210> 37 <211> 48 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 37 48 gctgctcctt ttaagctttg gggtcaaggc tcactagtca cagtctcc

<213> Artificial Sequence

tion at this a. . . ti distribution in the field take that total

<210> 38 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 38 24 tgacggtgcc cccgcgagtt cagg <210> 39 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 39 24 cctgaactcg cgggggcacc gtca <210> 40 <211> 33 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 40 33 aagetteegt egaatteatt tacceggaga cag <210> 41 <211> 37 <212> DNA

. . . . . .

That it fail is to man one in our man mil and in min

WO 99/58679 PCT/GB99/01434

20

<220>

<223> D scription of Artificial Sequence: Primer

<400> 41

actagtcgac atgaagtttc cttctcaact tctgctc

37

<210> 42

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
sequence

<400> 42

Thr Lys Leu Glu Ile Lys Arg Thr

<210> 43

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic sequence

<400> 43

Thr Lys Val Glu Ile Lys Arg Thr

1

5

<210> 44

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic sequence

<400> 44

Thr Lys Leu Glu Ile Arg Arg Thr

5

1

<210> 45

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic sequence

<400> 45

Thr Lys Val Glu Ile Arg Arg Thr

1 5

<210> 46

<211> 415

<212> DNA

<213> Mus musculus

<400> 46

actagtgtcc cttggccca gtctatgaaa tctgtacagt aataaactcc actgtcttca 60 gctcttaagc tgttcatttg caggtagaga cgacttttgg aatcatctct tgagatggtg 120 aacttccctt tcacagactc cgcataatgt gttgcataat tatcagattt caatctaatt 180 tcagcaaccc actcaagccc cttctctgga gactggcgga cccaagacat ccagtagcca 240 ctgaaagtaa atccagaggc tacacaggag agtttcatgg atcctccagg ttgcaccaag 300 cctcctccag actcctcaag cttcacttca ctctggaccc cttttaaaag aacaataaaa 360 aaaatcagcc caaaatccat ggtgaggtcc tgtgtgctga gtaactgtaa agctt 415

. •

PCT/GB99/01434

22

<210> 47 <211> 437 <212> DNA <213> Mus musculus <400> 47 cgtacgtttt atttccaact ttgtccccga gccgaacgtg aatggatact ctacaagttg 60 ttgacagtaa tacacaccca catcctcagc cttcactcta ctgatttcca gggtgaaatc 120 tgtgcctgac ccactgccac taaaccggtc tgagactcct gatgcacggg tggacatcaa 180 atacatcagg agctgaggag attgtcctgg tctctgcaga aaccaattca agtatgtctt 240 cccatcctta tacaggagac tcttactaga cctgcaggag atggaaactg attctccaga 300 agtgacagga ttggagagtt catcctgggt tatcacaata tccccactga ctccagagat 360 ccagaacata agcacccca gaaactgaac agagaacctc atggtgaggt cctgtgtgct 420 gagtaactgt aaagctt 437 <210> 48 <211> 348 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Humanised anti-CD23 antibody light chain variable region <400> 48 agccaccgta cgtttgatct ccaccttggt cccttggccg aacgtgaatg gatactctac 60 cagctgttga cagtaataaa ccccaacatc ctcagcctcc actctgctga ttttcagtgt 120 aaaatctgtg cctgatccac tgccactgaa cctgtcaggg acccctgatg cccgggtgga 180 catcaaatag atcaggagct gtggagactg ccctggcttc tgcaggtacc aattcaagta 240 tgtcttccca tccttataca ggagactctt actcgagcga caggagatgg aggccggctc 300 tccaggggtg acgggcaggg agagtggaga ctgagtcatc acaatatc 348 <210> 49 <211> 1335

<212> DNA

WO 99/58679

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Humanised
 anti-CD23 antibody heavy chain variable region

<400> 49 tcatttaccc ggagacaggg agaggctctt ctgcgtgtag tggttgtgca gagcctcatg 60 catcacggag catgagaaga cgttcccctg ctgccacctg ctcttgtcca cggtgagctt 120 gctgtagagg aagaaggagc cgtcggagtc cagcacggga ggcgtggtct tgtagttgtt 180 ctccggctgc ccattgctct cccactccac ggcgatgtcg ctgggataga agcctttgac 240 caggcaggtc aggctgacct ggttcttggt cagctcatcc cgggatgggg gcagggtgta 300 cacctgtggt tetegggget geeetttgge tttggagatg gttttetega tgggggetgg 360 gagggetttg ttggagacet tgcacttgta etecttgeca tteagecagt eetggtgeag 420 gacggtgagg acgctgacca cacggtacgt gctgttgtac tgctcctccc gcggctttgt 480 cttggcatta tgcacctcca cgccgtccac gtaccagttg aacttgacct cagggtcttc 540 gtggctcacg tccaccacca cgcatgtgac ctcaggggtc cgggagatca tgagggtgtc 600 cttgggtttt ggggggaaga ggaagactga cggtgccccc gcgagttcag gtgctgggca 660 cggtgggcat gtgtgagttt tgtcacaaga tttgggctcc actttcttgt ccaccttggt 720 gttgctgggc ttgtgattca cgttgcagat gtaggtctgg gtgcccaagc tgctggaggg 780 cacggtcacc acgctgctga gggagtagag tcctgaggac tgtaggacag ccgggaaggt 840 gtgcacgccg ctggtcaggg cgcctgagtt ccacgacacc gtcaccggtt cggggaagta 900 gtccttgacc aggcagccca gggccgctgt gcccccagag gtgctcttgg aggagggtgc 960 cagggggaag accgatgggc ccttggtgga ggctgaggag acggtgacta gtgttccctg 1020 gccccagtct atgaaatctg tacagtaata cacggctgtg tcctcggttt tcaggctgtt 1080 catttgcaga tacagtctag attttgaatc atctcttgag atggtgaatt tccccttcac 1140 agactccgca taatgtgttg cataattatc agatttcaat ctaatttcag caacccactc 1200 gagccccttc cctggagcct ggcggaccca ggacatccag tagccactga aagtgaatcc 1260 gctagctgca caggagagtc taagggaccc cccgggcttt accaagcctc ccccagactc 1320 1335 caccagetge acete

<210> 50

<211> 137

<212> PRT

<213> Mus musculus

<400> 50

Ala Leu Gln Leu Leu Ser Thr Gln Asp Leu Thr Met Asp Phe Gly Leu

1 5 10 15

n a tana m. a, an min min tana ena ena.

PCT/GB99/01434 WO 99/58679

Ile Phe Phe Ile Val Leu Leu Lys Gly Val Gln Ser Glu Val Lys Leu 

Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu 

Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Gly Tyr Trp Met Ser Trp 

Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg 

Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser Val Lys Gly 

Lys Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Arg Leu Tyr Leu Gln 

Met Asn Ser Leu Arg Ala Glu Asp Ser Gly Val Tyr Tyr Cys Thr Asp 

Phe Ile Asp Trp Gly Gln Gly Thr Leu 

<210> 51

<211> 145

<212> PRT

<213> Mus musculus

<400> 51

Ala Leu Gln Leu Leu Ser Thr Gln Asp Leu Thr Met Arg Phe Ser Val 

Gln Phe Leu Gly Val Leu Met Phe Trp Ile Ser Gly Val Ser Gly Asp 

Ile Val Ile Thr Gln Asp Glu Leu Ser Asn Pro Val Thr Ser Gly Glu 

WO 99/58679

75

Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys Asp 60 50 Gly Lys Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser Pro 80

Gln Leu Leu Met Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Ser Asp 90 95 85

70

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Glu Ile Ser 110 100 105

Arg Val Lys Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu Val 120 125 115

Glu Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg 135 130

Thr

65

145

<210> 52

<211> 116

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Humanised anti-CD23 antibody light chain variable region

<400> 52

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 10 15 5

Glu Pro Ala Ser Ile Ser Cys Arg Ser Lys Ser Leu Leu Tyr Lys 30 20 25

Asp Gly Lys Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 40 35

WO 99/58679 PCT/GB99/01434

26

Pro Gln Leu Leu Ile Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Pro 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu 85 90 95

Val Glu Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110

Arg Thr Val Ala

<210> 53

<211> 444

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Humanised anti-CD23 antibody heavy chain variable region.

<400> 53

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr
20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Glu Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu
50 55 60

Ser Val Lys Gly Lys Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Arg 65 70 75 80

. • 0

## WO 99/58679

PCT/GB99/01434

Leu	Туг	Leu	Gln	Met 85	Asn	Ser	Leu	Lys	Thr 90	Glu	Asp	Thr	Ala	Val 95	Tyr
Туг	Cys	Thr	Asp 100	Phe	Ile	Asp	Trp	Gly 105	Gln	Gly	Thr	Leu	Val 110	Thr	Val
Ser	Ser	Ala 115	Ser	Thr	Lys	Gly	Pro 120	Ser	Val	Phe	Pro	Leu 125	Ala	Pro	Ser
Ser	Lys 130	Ser	Thr	Ser	Gly	Gly 135	Thr	Ala	Ala	Leu	Gly 140	Cys	Leu	Val	Lys
Asp 145	Tyr	Phe	Pro	Glu	Pro 150	Val	Thr	Val	Ser	Trp 155	Asn	Ser	Gly	Ala	Leu 160
Thr	Ser	Gly	Val	His 165	Thr	Phe	Pro	Ala	Val 170	Leu	Gln	Ser	Ser	Gly 175	Leu
Tyr	Ser	Leu	Ser 180	Ser	Val	Val	Thr	Val 185	Pro	Ser	Ser	Ser	Leu 190	Gly	Thr
Gln	Thr	Tyr 195	Ile	Cys	Asn	Val	Asn 200	His	Lys	Pro	Ser	Asn 205	Thr	Lys	Val
Asp	Lys 210	Lys	Val	Glu	Pro	Lys 215	Ser	Cys	Asp	Lys	Thr 220	His	Thr	Cys	Pro
Pro 225	Cys	Pro	Ala	Pro	Glu 230	Leu	Ala	Gly	Ala	Pro 235	Ser	Val	Phe	Leu	Phe 240
Pro	Pro	Lys	Pro	Lys 245	Asp	Thr	Leu	Met	Ile 250	Ser	Arg	Thr	Pro	Glu 255	Val
Thr	Cys	Val	<b>V</b> al 260	Val	Asp	Val	Ser	His 265	Glu	Asp	Pro	Glu	Val 270	Lys	Phe
Asn	Trp	Tyr 275	Val	Asp	Gly	Val	Glu 280	Val	His	Asn	Ala	Lys 285	Thr	Lys	Pro

.

PCT/GB99/01434

28

Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300

Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320

Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335

Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg

Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365

Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 415

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435
440

. . . . .